错配修复缺陷在非转移性结直肠癌中的预后和预测价值
Prognostic and Predictive Values of Mismatch Repair Deficiency in Non-Metastatic Colorectal Cancer.
作者信息
Jin Zhaohui, Sinicrope Frank A
机构信息
Division of Oncology, Mayo Clinic and Mayo Comprehensive Cancer Center, Rochester, MN 55905, USA.
出版信息
Cancers (Basel). 2021 Jan 15;13(2):300. doi: 10.3390/cancers13020300.
Abstract
Colorectal cancer (CRC) is the third most commonly diagnosed cancer worldwide. Universal MMR/MSI testing is standard of care for all patients with newly diagnosed CRC based on multi-society guidelines in the United States. Such testing is intended to identify patients with Lynch Syndrome due to a germline mutation in an MMR gene, but also detects those with sporadic dMMR/MSI-high CRCs. The prognostic utility of MMR/MSI status in non-metastatic colorectal cancer has been studied extensively, yet more limited data are available for its predictive utility. Results have not been entirely consistent due to potential stage-related differences and limited numbers of dMMR/MSI-H patients included in the studies. In this review, we summarize the current evidence for the prognostic and predictive value of dMMR/MSI-H in non-metastatic CRC, and discuss the use of this biomarker for patient management and treatment decisions in clinical practice.
摘要
结直肠癌（CRC）是全球第三大常见诊断癌症。根据美国多学会指南，对所有新诊断的CRC患者进行普遍的错配修复（MMR）/微卫星高度不稳定（MSI）检测是标准治疗方法。此类检测旨在识别因MMR基因种系突变而患有林奇综合征的患者，但也能检测出散发性错配缺陷（dMMR）/MSI高的结直肠癌患者。MMR/MSI状态在非转移性结直肠癌中的预后效用已得到广泛研究，但其预测效用的数据则较为有限。由于潜在的分期相关差异以及研究中纳入的dMMR/MSI-H患者数量有限，结果并不完全一致。在本综述中，我们总结了dMMR/MSI-H在非转移性CRC中的预后和预测价值的当前证据，并讨论了该生物标志物在临床实践中用于患者管理和治疗决策的情况。
相似文献
1
Prognostic and Predictive Values of Mismatch Repair Deficiency in Non-Metastatic Colorectal Cancer.
Cancers (Basel). 2021 Jan 15;13(2):300. doi: 10.3390/cancers13020300.
2
Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment.
Eur J Cancer. 2022 Nov;175:136-157. doi: 10.1016/j.ejca.2022.07.020. Epub 2022 Sep 14.
3
The current value of determining the mismatch repair status of colorectal cancer: A rationale for routine testing.
Crit Rev Oncol Hematol. 2017 Aug;116:38-57. doi: 10.1016/j.critrevonc.2017.05.006. Epub 2017 May 20.
4
Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
Eur J Cancer. 2017 Nov;86:266-274. doi: 10.1016/j.ejca.2017.09.022. Epub 2017 Oct 19.
5
Microsatellite instability testing and its role in the management of colorectal cancer.
Curr Treat Options Oncol. 2015 Jul;16(7):30. doi: 10.1007/s11864-015-0348-2.
6
Clinical Aspects of Microsatellite Instability Testing in Colorectal Cancer.
Adv Biomed Res. 2018 Feb 16;7:28. doi: 10.4103/abr.abr_185_16. eCollection 2018.
7
Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
Arch Pathol Lab Med. 2018 Jan;142(1):17-25. doi: 10.5858/arpa.2017-0040-RA. Epub 2017 Nov 16.
8
Consequences of testing for mismatch repair deficiency of colorectal cancer in clinical practice.
Scand J Gastroenterol. 2018 May;53(5):632-636. doi: 10.1080/00365521.2017.1406534. Epub 2017 Nov 21.
9
Colorectal cancer due to deficiency in DNA mismatch repair function: a review.
Adv Anat Pathol. 2009 Nov;16(6):405-17. doi: 10.1097/PAP.0b013e3181bb6bdc.
10
Microsatellite Instability: Diagnosis, Heterogeneity, Discordance, and Clinical Impact in Colorectal Cancer.
Cancers (Basel). 2019 Oct 15;11(10):1567. doi: 10.3390/cancers11101567.
引用本文的文献
1
Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer.
Cancer Res. 2025 Aug 1;85(15):2788-2804. doi: 10.1158/0008-5472.CAN-24-3478.
2
What is the significance of mismatch repair deficiency in stage IV colon cancer?
J Gastrointest Oncol. 2025 Feb 28;16(1):330-332. doi: 10.21037/jgo-2025-74. Epub 2025 Feb 25.
3
Autophagy-related protein LC3β and its association with clinical-pathological characteristics, mismatch repair proteins and survival in colorectal carcinoma.
Front Med (Lausanne). 2025 Feb 13;12:1512127. doi: 10.3389/fmed.2025.1512127. eCollection 2025.
4
Distinct Clinical Characteristics and Predictors of Sporadic Mismatch Repair-Deficient Colorectal Cancer.
Gastro Hep Adv. 2024 Sep 26;4(2):100558. doi: 10.1016/j.gastha.2024.09.013. eCollection 2025.
5
Mismatch repair deficiency confers worse survival in stage IV colon cancer.
J Gastrointest Oncol. 2024 Dec 31;15(6):2521-2532. doi: 10.21037/jgo-24-387. Epub 2024 Dec 28.
6
DNA mismatch repair (MMR) genes expression in lung cancer and its correlation with different clinicopathologic parameters.
Sci Rep. 2025 Jan 6;15(1):885. doi: 10.1038/s41598-024-83067-2.
7
A Potent, Selective, Small-Molecule Inhibitor of DHX9 Abrogates Proliferation of Microsatellite Instable Cancers with Deficient Mismatch Repair.
Cancer Res. 2025 Feb 17;85(4):758-776. doi: 10.1158/0008-5472.CAN-24-0397.
8
Mismatch repair deficiency and microsatellite instability in urothelial carcinoma: a systematic review and meta-analysis.
BMJ Oncol. 2024 Jan;3(1). doi: 10.1136/bmjonc-2024-000335. Epub 2024 Apr 30.
9
A novel colorectal cancer test combining microsatellite instability and analysis: Clinical validation and impact on Lynch syndrome screening.
BJC Rep. 2024;2(1):48. doi: 10.1038/s44276-024-00072-8. Epub 2024 Jul 1.
10
Constitutional mismatch repair deficiency mimicking Lynch syndrome is associated with hypomorphic mismatch repair gene variants.
NPJ Precis Oncol. 2024 May 24;8(1):119. doi: 10.1038/s41698-024-00603-z.
本文引用的文献
1
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
J Clin Oncol. 2021 Feb 20;39(6):642-651. doi: 10.1200/JCO.20.01600. Epub 2020 Dec 23.
2
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
N Engl J Med. 2020 Dec 3;383(23):2207-2218. doi: 10.1056/NEJMoa2017699.
3
Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors.
Cancer Discov. 2020 Dec;10(12):1808-1825. doi: 10.1158/2159-8290.CD-20-0522. Epub 2020 Nov 2.
4
Identifying mismatch repair-deficient colon cancer: near-perfect concordance between immunohistochemistry and microsatellite instability testing in a large, population-based series.
Histopathology. 2021 Feb;78(3):401-413. doi: 10.1111/his.14233. Epub 2020 Oct 11.
5
Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors.
Int J Cancer. 2020 Nov 15;147(10):2948-2956. doi: 10.1002/ijc.33115. Epub 2020 Jun 18.
6
Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers.
Nat Med. 2020 Apr;26(4):566-576. doi: 10.1038/s41591-020-0805-8. Epub 2020 Apr 6.
7
Colorectal cancer statistics, 2020.
CA Cancer J Clin. 2020 May;70(3):145-164. doi: 10.3322/caac.21601. Epub 2020 Mar 5.
8
The Prognostic Implications of Tumor Infiltrating Lymphocytes in Colorectal Cancer: A Systematic Review and Meta-Analysis.
Sci Rep. 2020 Feb 25;10(1):3360. doi: 10.1038/s41598-020-60255-4.
9
Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study.
ESMO Open. 2020 Feb;5(1). doi: 10.1136/esmoopen-2019-000638.
10
The global, regional, and national burden of colorectal cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.
Lancet Gastroenterol Hepatol. 2019 Dec;4(12):913-933. doi: 10.1016/S2468-1253(19)30345-0. Epub 2019 Oct 21.
Zotero 插件